ESC 24: Hot Line & Late-breaking Science Video Collection

Published: 15 August 2024

  • Views:

    Views Icon 2589

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

What's hot at the ESC Congress 2024?

Stay ahead of the curve with our faculty-led coverage of the European Society of Cardiology Congress in London. From groundbreaking trials to expert insights, we've got you covered.

  • Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen. 
  • For a deeper dive into key hot line clinical trial data and its applicability, host, Dr Harriette Van Spall meets with principal investigators in her Late-Breaker Discussion series.
  • View a condensed summary of the crucial takeaways from each day in our Wrap-Up series led by Dr Mirvat Alasnag.
  • Our short, bite-sized Expert Interviews with select faculty will focus on data, take-home messages for practice and the future of their field.

Get ready for a deep dive into the latest cardiology research. Our coverage of the ESC Congress is coming soon.

More from this programme

Part 1

View From the Thoraxcenter: What's Hot at ESC 24?

2 sessions
ESC Congress 2024 Hot Line Wrap Up Watch now
ESC Congress 2024 Hot Line Preview Watch now

Part 2

Daily Wrap Ups with Dr Alasnag and Dr Al-Shaibi

4 sessions
ESC Day 1 Wrap Up: New Guidelines, HELIOS-B, ABYSS & STOP-or-NOT Watch now
ESC Day 2 Wrap-Up: NOTION-3, RESHAPE-HF2, TRI.Fr & More Watch now
Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi Watch now
Day 4 Wrap-Up: OCCUPI, REC-CAGEFREE I, AEGIS-II & More Watch now

Part 3

Hot-line Discussions with Dr Harriette Van Spall

5 sessions
AβYSS: Beta Blocker Interruption After Uncomplicated MI Watch now
RHEIA: TAVR vs SAVR in Women with Severe AS Watch now
OCEANIC-AF: Asundexian Vs Apixaban in Atrial Fibrillation Watch now
SWEDEGRAFT: No-touch Vein Graft in CABG Watch now
FINEARTS-HF: Finerenone HFmEF & HFpEF Watch now

Part 4

Expert Interviews

13 sessions
Bridging the Gap in Heart Failure Guideline Implementation from a Specialist Nurse Perspective Watch now
MATTERHORN: M-TEER vs Surgery in Heart Failure Watch now
MRAs in Heart Failure Watch now
FINE-HEART: Finerenone in HF & CKD Watch now
STEEER-AF: Stroke Prevention & Rhythm Control Therapy Watch now
NOTION-3: FFR Guided PCI in TAVI Watch now
EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD Watch now
SENIOR RITA: Invasive Vs Conservative Strategy for Older Patients with MI Watch now
EARTH-STEMI: Complete Vs Culprit-Only Revascularization in Older Patients Watch now
SCOFF: Fasting vs. Non-Fasting: Impact on Cardiac Catheterization Outcomes Watch now
GUARD-AF: Atrial Fibrillation Screening to Reduce Stroke in Elderly Individuals Watch now
SHAM-PVI: Sham Study of Pulmonary Vein Isolation in Symptomatic Atrial Fibrillation Watch now
POPular PAUSE TAVI: Continuation or interruption of OAC During TAVI Watch now

Part 5

Highlights

2 sessions
3 Trials That Will Change My Practice With Dr Muthiah Vaduganathan Watch now
3 Trials That Will Change My Practice With Dr Michelle Kittleson Watch now

Part 6

Guidelines

2 sessions
New Guidelines for the Management of Atrial Fibrillation Watch now
New Guidelines for the Management of Aortic Diseases Watch now

About the episode

ESC Congress 2024 — OCEANIC-AF was halted early due to a lack of efficacy in 2023. Investigators shared details of the trial at ESC, comparing asundexian against apixaban in patients with atrial fibrillation at risk of stroke.

Host Dr Harriette Van Spall (McMaster University, Hamilton, Canada) sits down with primary investigator Dr Manesh R Patel (Duke University Health System, USA) to discuss the much-anticipated data from the OCEANIC-AF trial (NCT05643573; Bayer).

This multicentre, international, randomised, phase 3 study compared asundexian with apixaban in patients with atrial fibrillation and a high risk of stroke. Investigators enrolled 14,830 patients from 1,069 locations across various countries. The primary outcome measure was the time to first occurrence of a composite of stroke or systemic embolism.

Data revealed at ESC suggest that asundexian was inferior to apixaban (hazard ratio [HR] 3.79; 95% confidence interval [CI] 2.46-5.83) for stroke and systemic embolism prevention, but was associated with fewer major bleeding events (0.2% vs. 0.7%; HR 0.44; 95% CI 0.34-0.57). 

Recorded on-site at ESC Congress 2024, London.

Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology. 

Faculty Biographies

Manesh R Patel

Manesh R Patel

Professor of Medicine / Chief, Division of Clinical Pharmacology / Chief, Division of Cardiology

Manesh Patel is the Chief of the Division of Cardiology and the Division of Clinical Pharmacology.  His clinical interests include diagnostic and interventional coronary angiography, peripheral angiography and endovascular intervention.  His is involved in several clinical trials involving patients with cardiovascular disease and in cardiac imaging.  He is also the Chair of the American College of Cardiology Task Force for Appropriate Use Criteria for Cardiovascular Procedures and is Chair of the American Heart Association Diagnostic and Interventional Cath Committee.

View full profile
Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.

She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.

Dr Van Spall is an Editorial Board…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.